Table 1 Basic sample demographics and clinical information.

From: Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study

Characteristic

All

CYP2C19

 

CYP2D6

N = 178

NM (N = 71)

IM + PM (N = 56)

RM + UM (N = 50)

p-valuea

NM (N = 99)

IM + PM (N = 71)

p-valueb

Age

35.43 (12.77)

35.04 (12.96)

35.54 (12.75)

35.94 (12.88)

0.888

36.61 (13.18)

34.44 (12.53)

0.268

Sex

    

0.646

  

0.755

Female

110 (62%)

41 (58%)

35 (62%)

33 (66%)

 

59 (60%)

44 (62%)

 

Male

68 (38%)

30 (42%)

21 (38%)

17 (34%)

 

40 (40%)

27 (38%)

 

Ancestryc

    

<0.001 ***

  

0.564

Non-European [African (4), East Asian (14), Latin American (9), South Asian (5), South East Asian (4), and mixed ancestry (13)]

49 (28%)

14 (20%)

27 (48%)

8 (16%)

 

24 (24%)

20 (28%)

 

European

129 (72%)

57 (80%)

29 (52%)

42 (84%)

 

75 (76%)

51 (72%)

 

Previous AD treatment for current MDE

    

0.104

  

0.334

None

104 (58%)

35 (49%)

38 (68%)

30 (60%)

 

54 (55%)

44 (62%)

 

1+

74 (42%)

36 (51%)

18 (32%)

20 (40%)

 

45 (45%)

27 (38%)

 

ESC dose at Week 8

    

0.599

  

>0.999

10 mg

177 (99%)

71 (100%)

55 (98%)

50 (100%)

 

98 (99%)

71 (100%)

 

20 mg

1 (0.6%)

0 (0%)

1 (1.8%)

0 (0%)

 

1 (1.0%)

0 (0%)

 

ESC dose at Week 16

    

0.633

  

0.023 *

10 mg

16 (9.8%)

5 (7.5%)

6 (12%)

5 (11%)

 

5 (5.4%)

11 (17%)

 

15 mg

2 (1.2%)

2 (3.0%)

0 (0%)

0 (0%)

 

2 (2.2%)

0 (0%)

 

20 mg

145 (89%)

60 (90%)

43 (88%)

41 (89%)

 

86 (92%)

54 (83%)

 

Phase II treatment arm

    

0.959

  

0.308

ESC

81 (46%)

33 (46%)

25 (45%)

22 (44%)

 

41 (41%)

35 (49%)

 

ESC + ARI

97 (54%)

38 (54%)

31 (55%)

28 (56%)

 

58 (59%)

36 (51%)

 

Baseline MADRS Score

29.98 (5.50)

30.06 (5.26)

29.75 (5.36)

30.10 (6.11)

0.953

30.60 (5.82)

29.14 (5.09)

0.122

CYP2C19 Metabolizer Groups

    

–

  

0.510

NM

71 (40%)

–

–

–

 

42 (42%)

26 (37%)

 

IM + PM

56 (32%)

–

–

–

 

28 (28%)

26 (37%)

 

RM + UM

50 (28%)

–

–

–

 

29 (29%)

19 (27%)

 

CYP2D6 Metabolizer Groups

    

0.510

  

–

NM

99 (58%)

42 (62%)

28 (52%)

29 (60%)

 

–

–

 

IM + PM

71 (42%)

26 (38%)

26 (48%)

19 (40%)

 

–

–

 
  1. Mean (with standard deviation) and frequency are displayed for continuous and categorical variables, respectively.
  2. AD Antidepressant, ARI aripiprazole, ESC escitalopram, IM intermediate metabolizer, MADRS Montgomery–Åsberg depression rating scale, MDE major depressive episode, NM normal metabolizer, PM poor metabolizer, RM rapid metabolizer, SD standard deviation, UM ultra-rapid metabolizer.
  3. *p < 0.05; **p < 0.01; ***p < 0.001. Statistically significant differences between metabolizer groups are indicated in bold.
  4. aKruskal–Wallis rank sum test; Pearson’s Chi-squared test; Fisher’s exact test.
  5. bWilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test.
  6. cCategories for ancestry are adapted from the International Genome Sample Resource 1000 Genomes Project (http://www.internationalgenome.org/category/population/).
Back to article page